PITTSBORO, N.C., Oct. 7, 2020 /PRNewswire/ — Propella Therapeutics Inc. (Propella), a leader in the development of innovative best-in-class prescription products, today announced the issuance of a U.S. patent for a new drug treatment for metastatic prostate cancer. The patent covers new molecules that are designed to provide significant advantages over the current standard of care. The patent, titled Abiraterone Prodrugs, […]
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2020-10-07 14:56:572020-10-07 14:56:58Propella Therapeutics Granted U.S. Patent for New Treatment for Metastatic Prostate Cancer
Vizuri Health Sciences LLC has completed a strategic reorganization to form two new corporations. The new entities are Propella Therapeutics Inc., focusing on prescription drugs, and Vizuri Health Sciences Consumer Healthcare Inc., developing non-prescription pain management products.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00neilhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgneil2020-06-02 11:11:022020-06-02 11:28:17Press Release: Leading Drug Innovator Reorganizes into Two Separate Companies
The American College of Rheumatology (ACR), an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2020-01-23 20:58:432020-05-05 19:54:01Press Release: New Osteoarthritis (OA) Treatment Guidelines Issued … Expert Medical Organization Conditionally Recommends the Use of Topical Capsaicin for Pain due to OA of the Knee
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00neilhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgneil2019-11-12 19:45:002020-05-05 19:54:42Presentation: A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2019-10-29 18:25:002020-05-05 19:54:52Press Release: Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting
Propella Therapeutics Granted U.S. Patent for New Treatment for Metastatic Prostate Cancer
/in all, press release /by altusdevsite_4grsdfPITTSBORO, N.C., Oct. 7, 2020 /PRNewswire/ — Propella Therapeutics Inc. (Propella), a leader in the development of innovative best-in-class prescription products, today announced the issuance of a U.S. patent for a new drug treatment for metastatic prostate cancer. The patent covers new molecules that are designed to provide significant advantages over the current standard of care. The patent, titled Abiraterone Prodrugs, […]
Press Release: Leading Drug Innovator Reorganizes into Two Separate Companies
/in all, press release /by neilVizuri Health Sciences LLC has completed a strategic reorganization to form two new corporations. The new entities are Propella Therapeutics Inc., focusing on prescription drugs, and Vizuri Health Sciences Consumer Healthcare Inc., developing non-prescription pain management products.
Press Release: New Osteoarthritis (OA) Treatment Guidelines Issued … Expert Medical Organization Conditionally Recommends the Use of Topical Capsaicin for Pain due to OA of the Knee
/in all, press release /by altusdevsite_4grsdfThe American College of Rheumatology (ACR), an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.
News: Well-Tolerated Topical Capsaicin Formulation Reduces Knee OA Pain
/in all, news /by neilNews coverage of our CGS-200-5 Phase 2 results for OA pain of the knee. Read Article
Presentation: A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
/in all, presentation /by neilView the results of our Phase 2 clinical study of CGS-200-5 presented at the 2019 ACR Annual Meeting View Abstract
Press Release: Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting
/in all, press release /by altusdevsite_4grsdfVizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting